Forbion Promotes Mathias Vinther, PhD to Partner within its Growth Strategy
Naarden, The Netherlands – 21 October 2025 - Forbion is pleased to announce the promotion of Mathias Vinther, PhD to Partner within its Growth Fund. Mathias joined Forbion in March 2022 as Principal, and has been instrumental in the evaluation, development, and support of numerous growth-stage biotech opportunities. During his time at Forbion, he has led due diligence on opportunities across Europe and the United States, supported portfolio companies such as Navigator, Vectiv Bio, and Capstan on business and regulatory strategy, and contributed to several successful exits and IPOs.
As Partner, Mathias will play an expanded leadership role in shaping the strategy for the Growth Fund, making investment decisions, guiding portfolio companies, and strengthening Forbion’s network of scientific and industry relationships.
Mathias has distinguished himself through his deep science-driven investment approach and his commitment to scaling companies that deliver meaningful patient impact. We are delighted to elevate him to Partner and look forward to his leadership in driving the Growth team’s next phase."
Dirk Kersten
Managing Partner
It’s an honour to take on the role of Partner at Forbion. The Growth team is in a strong position to partner with outstanding companies in Europe and the U.S. that are developing the next generation of therapies. I look forward to working with our entrepreneurs, leveraging our experience and resources to help them succeed."
Mathias Vinter, PhD
Partner
Mathias holds a PhD in Nanomedicine from Aarhus University, where his research focused on immunotherapy and drug delivery, and he has conducted additional studies at UC Berkeley and Harvard Medical School.
***ENDS***